Adalimumab treatment in adult patients with refractory non-infectious uveitis

Authors : Ebru ESEN, Püren IŞIK, Selçuk SIZMAZ, Nihal DEMİRCAN

Pages : 457-462

Doi:10.17826/cumj.1224611

View : 51 | Download : 203

Publication Date : 2023-07-02

Article Type : Research Paper

Abstract :Purpose: To assess the efficacy of adalimumab treatment in patients with refractory non-infectious uveitis. Materials and Methods: A retrospective analysis was carried out on patients with chronic non-infectious uveitis treated with adalimumab for longer than 12 months. All patients had active intraocular inflammation and were nonresponsive to other immunosuppressive agents before initiating adalimumab treatment. Results: Twenty-one patients insert ignore into journalissuearticles values(39 eyes); were treated with adalimumab for a mean duration of 26.2 ± 13.2 months. Eleven patients insert ignore into journalissuearticles values(52.4%); remained relapse-free during the treatment. In only one patient insert ignore into journalissuearticles values(4.8%); adalimumab was switched to another drug due to insufficient response. Adalimumab treatment was discontinued in five patients insert ignore into journalissuearticles values(23.8%); after an attack-free period of at least 18 months. Conclusion: Adalimumab is an effective and well-tolerated therapeutic option for patients with refractory non-infectious uveitis, to achieve and maintain disease quiescence.
Keywords : Adalimumab, enfeksiyöz olmayan üveit, dirençli üveit, non infectious uveitis, refractory uveitis